Related Experiment Video
Updated: Feb 20, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
Advancing CAR T-cell Therapies with Artificial Intelligence: Opportunities and Challenges
Fabio Luciani1, Arman Safavi1, Puneeth Guruprasad2,3
1Systems Immunology and Immunogenomics, School of Biomedical Sciences, UNSW Sydney, Sydney, Australia.
None:
Artificial intelligence could enhance chimeric antigen receptor T-cell therapy outcomes through optimization of all steps, from target identification, vector design, and manufacturing to personalized data-driven clinical decisions. In this report, we highlight steps toward unlocking this potential, including the need for standardized, comprehensive data repositories as a way for addressing barriers to artificial intelligence learning, such as data heterogeneity and patient privacy.
Related Concept Videos
Tumor Immunotherapy
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...

